PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), has received approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD.
At the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia, Arrowhead Pharmaceuticals unveiled the phase 2 clinical data for plozasiran (ARO-APOC3) and zodasiran (ARO-ANG3).
CellProthera is moving forward with its cell therapy which regenerates damaged tissue following a severe heart attack, restoring cardiac function and effectively mending a broken heart.
BioCardia has recently completed the submission of CardiAMP Cell Therapy System to Japan’s Pharmaceutical and Medical Device Agency (PMDA) towards approval for the indication of ischemic heart failure (HF) with reduced ejection fraction.
Neurimmune has announced that primary results of its phase 1 proof-of-concept study of NI006, a recombinant human antibody to deplete amyloid deposits in ATTR cardiomyopathy, have been presented in Prague at Heart Failure 2023, a scientific congress of...